Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Current Deferred Revenue (2016 - 2017)

Coherus Oncology's Current Deferred Revenue history spans 5 years, with the latest figure at $669000.0 for Q1 2017.

  • For Q1 2017, Current Deferred Revenue fell 98.65% year-over-year to $669000.0; the TTM value through Mar 2017 reached $669000.0, down 98.65%, while the annual FY2016 figure was $892000.0, 98.2% down from the prior year.
  • Current Deferred Revenue for Q1 2017 was $669000.0 at Coherus Oncology, down from $892000.0 in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $61.3 million in Q2 2016 and bottomed at $300000.0 in Q1 2014.
  • The 5-year median for Current Deferred Revenue is $22.8 million (2014), against an average of $23.7 million.
  • The largest annual shift saw Current Deferred Revenue skyrocketed 7500.0% in 2015 before it plummeted 98.65% in 2017.
  • A 5-year view of Current Deferred Revenue shows it stood at $14.3 million in 2013, then surged by 59.63% to $22.8 million in 2014, then skyrocketed by 117.64% to $49.6 million in 2015, then tumbled by 98.2% to $892000.0 in 2016, then fell by 25.0% to $669000.0 in 2017.
  • Per Business Quant, the three most recent readings for CHRS's Current Deferred Revenue are $669000.0 (Q1 2017), $892000.0 (Q4 2016), and $1.4 million (Q3 2016).